FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030402361> ?p ?o ?g. }

• W2030402361 abstract "The lack of treatment for worried-well patients with high-grade prostatic intraepithelial neoplasia combined with issues of recurrence and hormone resistance in prostate cancer survivors remains a major public health obstacle. The long latency of prostate cancer development provides an opportunity to intervene with mechanistically-based agents at various stages of disease progression. Preclinical studies and immunohistochemical analyses of human prostate adenocarcinoma tissues have implicated the mammalian target of rapamycin (mTOR) signaling pathway in the progression of prostate cancer and its transition to androgen independence, suggesting mTOR as a potential target for new therapies. Preclinical studies in human prostate cancer cells also show that there is cross-talk between mTOR and androgen receptor signaling, a process critical for prostate cancer growth and survival. We have previously shown that the synthetic organoselenium compound p-XSC effectively inhibits cell viability and down-regulates androgen receptor expression and transcriptional activity in androgen responsive (AR) and androgen independent (AI) human prostate cancer cells; the naturally occurring selenomethionine was either ineffective or weakly active at non-physiological levels. Therefore, we focused our study on the effects of p-XSC and we hypothesized that it inhibits prostate cancer cell growth by interfering with mTOR signaling and that inhibition of this pathway may be linked to down-regulation of androgen receptor signaling in these cells. Here we show that p-XSC inhibits phosphorylation of mTOR in both AR LNCaP and AI LNCaP C4-2 human prostate cancer cells. This inhibition is attenuated by stimulation with androgens in AR LNCaP but not AI C4-2 cells, emphasizing a cross-talk between the two pathways. p-XSC also decreases mTOR binding to mTOR complex 2 (mTORC2) protein Rictor in AR LNCaP and AI C4-2 cells and inhibits the phosphorylation of mTORC2 downstream target Akt. Since p-XSC appears to be inhibiting mTORC2 as well as androgen signaling, we further hypothesized that the combination of p-XSC with rapamycin, which primarily targets mTORC1, may be a superior approach to inhibit prostate cancer cell growth than either agent alone. Our data clearly support this hypothesis. Validation of mTOR as a target of selenium in prostate cancer will provide evidence for its potential role against advanced and hormone refractory prostate disease either individually or in combination with therapies that target other signaling pathways. Support: NIH CA111842, DOD W81XWH-08-1-0297 Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 574." @default.
• W2030402361 created "2016-06-24" @default.
• W2030402361 creator A5005144004 @default.
• W2030402361 creator A5008059478 @default.
• W2030402361 creator A5043342415 @default.
• W2030402361 creator A5058074461 @default.
• W2030402361 creator A5080527856 @default.
• W2030402361 date "2010-04-15" @default.
• W2030402361 modified "2023-09-26" @default.
• W2030402361 title "Abstract 574: 1,4-phenylenebis(methylene)selenocyanate (p-XSC) inhibits mammalian target of rapamycin complex 2 (mTORC2) signaling in prostate cancer cells" @default.
• W2030402361 doi "https://doi.org/10.1158/1538-7445.am10-574" @default.
• W2030402361 hasPublicationYear "2010" @default.
• W2030402361 type Work @default.
• W2030402361 sameAs 2030402361 @default.
• W2030402361 citedByCount "0" @default.
• W2030402361 crossrefType "proceedings-article" @default.
• W2030402361 hasAuthorship W2030402361A5005144004 @default.
• W2030402361 hasAuthorship W2030402361A5008059478 @default.
• W2030402361 hasAuthorship W2030402361A5043342415 @default.
• W2030402361 hasAuthorship W2030402361A5058074461 @default.
• W2030402361 hasAuthorship W2030402361A5080527856 @default.
• W2030402361 hasConcept C121608353 @default.
• W2030402361 hasConcept C126322002 @default.
• W2030402361 hasConcept C134018914 @default.
• W2030402361 hasConcept C2776235491 @default.
• W2030402361 hasConcept C2779723316 @default.
• W2030402361 hasConcept C2780192828 @default.
• W2030402361 hasConcept C502942594 @default.
• W2030402361 hasConcept C61367390 @default.
• W2030402361 hasConcept C62478195 @default.
• W2030402361 hasConcept C71924100 @default.
• W2030402361 hasConcept C86554907 @default.
• W2030402361 hasConcept C86803240 @default.
• W2030402361 hasConcept C95444343 @default.
• W2030402361 hasConceptScore W2030402361C121608353 @default.
• W2030402361 hasConceptScore W2030402361C126322002 @default.
• W2030402361 hasConceptScore W2030402361C134018914 @default.
• W2030402361 hasConceptScore W2030402361C2776235491 @default.
• W2030402361 hasConceptScore W2030402361C2779723316 @default.
• W2030402361 hasConceptScore W2030402361C2780192828 @default.
• W2030402361 hasConceptScore W2030402361C502942594 @default.
• W2030402361 hasConceptScore W2030402361C61367390 @default.
• W2030402361 hasConceptScore W2030402361C62478195 @default.
• W2030402361 hasConceptScore W2030402361C71924100 @default.
• W2030402361 hasConceptScore W2030402361C86554907 @default.
• W2030402361 hasConceptScore W2030402361C86803240 @default.
• W2030402361 hasConceptScore W2030402361C95444343 @default.
• W2030402361 hasLocation W20304023611 @default.
• W2030402361 hasOpenAccess W2030402361 @default.
• W2030402361 hasPrimaryLocation W20304023611 @default.
• W2030402361 hasRelatedWork W162420458 @default.
• W2030402361 hasRelatedWork W1777295695 @default.
• W2030402361 hasRelatedWork W1973259574 @default.
• W2030402361 hasRelatedWork W2057300149 @default.
• W2030402361 hasRelatedWork W2064425366 @default.
• W2030402361 hasRelatedWork W2077807612 @default.
• W2030402361 hasRelatedWork W2084361414 @default.
• W2030402361 hasRelatedWork W2092337416 @default.
• W2030402361 hasRelatedWork W2103347688 @default.
• W2030402361 hasRelatedWork W2107204247 @default.
• W2030402361 hasRelatedWork W2127782142 @default.
• W2030402361 hasRelatedWork W2223830426 @default.
• W2030402361 hasRelatedWork W2281083696 @default.
• W2030402361 hasRelatedWork W2532154357 @default.
• W2030402361 hasRelatedWork W2740620335 @default.
• W2030402361 hasRelatedWork W2783262509 @default.
• W2030402361 hasRelatedWork W2891421071 @default.
• W2030402361 hasRelatedWork W3092074436 @default.
• W2030402361 hasRelatedWork W3092885945 @default.
• W2030402361 hasRelatedWork W2498839141 @default.
• W2030402361 isParatext "false" @default.
• W2030402361 isRetracted "false" @default.
• W2030402361 magId "2030402361" @default.
• W2030402361 workType "article" @default.